NCT06787911View on ClinicalTrials.gov

Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

September 30, 2026

Conditions

Thyroid Cancer

Interventions

DRUG

Donafeib with Sintilimab

Patients receive Donafenib and PD-1 antibody Sintilimab

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Yu Wang

OTHER